JET2019

講演情報

Poster session

[POSTER] Poster session

2019年2月24日(日) 09:00 〜 18:20 ポスター会場

[MP-18] Short term clinical outcome of long time inflation treatment for denovo femoro-popliteal
artery lesion.

Kohei Kawamura (Okayama City Hospital, Department of Cardiology)

Background: It is unknown about optimal inflation time for SFA lesion, and about whether the limb prognosis is different depending on inflation time. Objectives: To investigate the short-term clinical outcome of long time inflation treatment for denovo femoro-popliteal artery lesion in our center. Methods and Results: We retrospectively analyzed clinical outcomes of consecutive 107 cases treated for denovo femoro-popliteal artery lesion from May 2015 to June 2018 in our center. Among them, from May 2015 through December 2016, we treated by short-inflation therapy (group SI), from January 2017 through June 2018, we treated by long-inflation therapy which is longer than 5 minutes (group LI). After exclusion of 21 stenting cases, 5 procedural failure cases and 1 ALI case, 22 cases were allocated to group LI, other 56 cases to group SI. We assessed composite of major amputation and re-intervention (MALE) as primary outcome. Results: The median follow up period was 182.7±110.2 days in group LI, 385.3 ±343.1days in group SI. The median inflation time was 526.8±95.9 seconds in group LI, 129.6±56.4 seconds in group SI. (p<0.0001) Event rate of MALE did not differ between the groups (22.7%, group LI v.s 16.1% group SI, p=0.75) Multivariate analysis identified non-ambulatory (odds ratio 2.20, p=0.03) and diabetes (odds ratio 1.74, p=0.047) as an independent positive predictor of MALE. 2 patients of group LI and 4 cases of group SI died during follow-up period, but there was no significant different between 2 groups (9.1% v.s 7.1%, p=0.77). Also the rate of angiographic restenosis rate were similar between 2 groups. (22.7% v.s 17.9%, p=0.75) Conclusions: Only long-time inflation treatment for denovo SFA lesions do not have an influence on limb prognosis. Additional therapy such as DCB and DES are necessary for improving the prognosis.